Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Sleep apnoea and hypertension: time for recommendations

Patrick Lévy, Walter T. McNicholas
European Respiratory Journal 2013 41: 505-506; DOI: 10.1183/09031936.00007213
Patrick Lévy
*University Grenoble Alpes, HP2 laboratory, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter T. McNicholas
#Sleep Research Laboratory, University College Dublin, St Vincent's University Hospital, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Hypertension can be caused by obstructive sleep apnoea (OSA), as now recognised in international guidelines [1, 2]. The relationship between OSA and hypertension is well established, which has important consequences for the cardiovascular system [3, 4]. Many studies have shown an increase in the incidence and prevalence of hypertension in patients with OSA, independent of confounding factors, such as anthropometric parameters, alcohol consumption and smoking [5–8]. OSA is a recognised cause of hypertension that should be considered in any patient with high blood pressure, particularly in those with resistant hypertension [1, 2]. More than 50% of patients with OSA are hypertensive [7, 9] and more than 80% of patients with resistant hypertension also have OSA [10]. Hypertension related to OSA is predominantly nocturnal with a frequent non-dipper profile (which corresponds to a limited fall in nocturnal blood pressure) and an increase in diastolic blood pressure in the majority of patients [9, 11].

The mechanisms linking sleep apnoea and hypertension have been extensively reviewed [3, 4, 12]. There is increased sympathetic activity, which has been demonstrated in patients with OSA using sympathetic micro-neurography of the nerves supplying muscles, and also using plasma and urinary catecholamine assays. Potential mechanisms contributing to OSA-related hypertension include endothelial dysfunction leading to inhibition of nitric oxide production, decreased vasodilatation, and increased vasoconstriction; systemic inflammation, which favours endothelial dysfunction; oxidative stress, which results in the production of reactive oxygen species and causes vasoconstriction as a result of nitric oxide synthase blockade, increased generation of endothelin-1, and activation of angiotensin II; activation of the renin–angiotensin–aldosterone system, which increases plasma aldosterone levels; and metabolic anomalies leading to hyperinsulinism and resistance to the metabolic effects of leptin, the adipocyte-derived hormone. Activation of the endothelin system results in vasoconstriction and depressed baroreflexes. A genetic contribution to the association between OSA and hypertension might also exist, but there is currently only a limited amount of data available to support this possibility. Although not fully understood, the role of hypoxia in promoting an increase in blood pressure appears prominent, as evidenced both in animal models [13] and more recently in a model developed in normal volunteers [14, 15]. In this latter model, it is notable that intermittent hypoxia during the night did not produce an immediate increase in blood pressure, presumably due to vasodilation occurring in response to intermittent hypoxia counteracting the effects of sympathetic activation [15]. However, there was a sustained increase in sympathetic activity that seems to be responsible for the daytime increase in blood pressure observed in these subjects after only one night of intermittent hypoxia, which is more pronounced after 13 nights, and still tending to persist after 5 days of intermittent hypoxia exposure withdrawal [15]. Blood pressure lowering response to continuous positive airway pressure (CPAP) treatment appears to be dependent on sleep apnoea severity [16–18]. Whether sleepiness is important in predicting the CPAP-associated reduction in blood pressure is still debated [18–20], but probably unlikely [21]. In any case, the reduction in blood pressure obtained when treating OSA seems relatively limited [18, 21, 22] and far less than that previously reported in earlier studies [17], even when including only hypertensive patients [21, 22]. More recently, however, it has been clearly demonstrated that a reduction in blood pressure, as well as a reduced incidence of hypertension, cannot be achieved unless a minimum of 4–6 h of CPAP usage is achieved [8, 23].

In this issue of the European Respiratory Journal, Parati et al. [24] report the work performed by a panel of experts participating in the European Union COST (Cooperation in Scientific and Technological research) Action B26 on OSA, with the endorsement of the European Respiratory Society (ERS) and the European Society of Hypertension (ESH). This group of experts has produced, between 2005 and 2010, a number of recommendations in the fields of sleep apnoea and cardiovascular disease [3, 25], management of OSA [26], and driving [27, 28]. Since OSA is now a recognised cause of hypertension, this group, which includes respiratory physicians, sleep experts and cardiologists, considered that there was a need to review the current knowledge and propose recommendations for clinicians and researchers. Importantly, this position paper is not only endorsed by the two scientific societies concerned, i.e. the ESH and ERS, but is also jointly published [24, 25].

The document is aimed at addressing the current state of the art in epidemiology, pathophysiology, diagnostic procedures and treatment options for optimum management of OSA in cardiovascular patients, as well as for the management of arterial hypertension in OSA patients. The recommendations have the objective of reminding cardiovascular experts to consider the occurrence of sleep-related breathing disorders in patients with high blood pressure, and also for sleep and breathing physicians to consider the occurrence of hypertension in patients with sleep-related breathing disorders. We believe that this cooperative work provides a highly valuable body of knowledge, which stresses the need to continuously update the current national and international guidelines on the relationships between these highly prevalent disorders.

Footnotes

  • Statement of Interest

    None declared.

  • ©ERS 2013

REFERENCES

  1. ↵
    1. Baguet JP,
    2. Narkiewicz K,
    3. Mallion JM
    . Update on hypertension management: obstructive sleep apnea and hypertension. J Hypertens 2006; 24: 205–208.
    OpenUrlPubMedWeb of Science
  2. ↵
    1. Chobanian AV,
    2. Bakris GL,
    3. Black HR,
    4. et al
    . The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. JAMA 2003; 289: 2560–2572.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. McNicholas WT,
    2. Bonsignore MR,
    3. COST action B26 MC
    . Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007; 29: 156–178.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Baguet JP,
    2. Barone-Rochette G,
    3. Tamisier R,
    4. et al
    . Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol 2012; 9: 679–688.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nieto FJ,
    2. Young TB,
    3. Lind BK,
    4. et al
    . Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep heart health study. JAMA 2000; 283: 1829–1836.
    OpenUrlCrossRefPubMedWeb of Science
    1. Peppard PE,
    2. Young T,
    3. Palta M,
    4. et al
    . Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378–1384.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Baguet JP,
    2. Hammer L,
    3. Levy P,
    4. et al
    . Night-time and diastolic hypertension are common and underestimated conditions in newly diagnosed apnoeic patients. J Hypertens 2005; 23: 521–527.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Marin JM,
    2. Agusti A,
    3. Villar I,
    4. et al
    . Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012; 307: 2169–2176.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Baguet JP,
    2. Levy P,
    3. Barone-Rochette G,
    4. et al
    . Masked hypertension in obstructive sleep apnea syndrome. J Hypertens 2008; 26: 885–892.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Logan AG,
    2. Perlikowski SM,
    3. Mente A,
    4. et al
    . High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19: 2271–2277.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Grote L,
    2. Hedner J,
    3. Peter JH
    . Mean blood pressure, pulse pressure and grade of hypertension in untreated hypertensive patients with sleep-related breathing disorder. J Hypertens 2001; 19: 683–690.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Levy P,
    2. Tamisier R,
    3. Arnaud C,
    4. et al
    . Sleep deprivation, sleep apnea and cardiovascular diseases. Front Biosci (Elite Ed) 2012; 4: 2007–2021.
    OpenUrlPubMed
  12. ↵
    1. Brooks D,
    2. Horner RL,
    3. Kimoff RJ,
    4. et al
    . Effect of obstructive sleep apnea versus sleep fragmentation on responses to airway occlusion. Am J Respir Crit Care Med 1997; 155: 1609–1617.
    OpenUrlPubMedWeb of Science
  13. ↵
    1. Tamisier R,
    2. Gilmartin GS,
    3. Launois SH,
    4. et al
    . A new model of chronic intermittent hypoxia in humans: effect on ventilation, sleep, and blood pressure. J Appl Physiol 2009; 107: 17–24.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Tamisier R,
    2. Pepin JL,
    3. Remy J,
    4. et al
    . Fourteen nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur Respir J 2011; 37: 119–128.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Pepperell JC,
    2. Ramdassingh-Dow S,
    3. Crosthwaite N,
    4. et al
    . Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359: 204–210.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Becker HF,
    2. Jerrentrup A,
    3. Ploch T,
    4. et al
    . Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003; 107: 68–73.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Haentjens P,
    2. Van Meerhaeghe A,
    3. Moscariello A,
    4. et al
    . The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007; 167: 757–764.
    OpenUrlCrossRefPubMedWeb of Science
    1. Barbe F,
    2. Mayoralas LR,
    3. Duran J,
    4. et al
    . Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness: a randomized, controlled trial. Ann Intern Med 2001; 134: 1015–1023.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Robinson GV,
    2. Smith DM,
    3. Langford BA,
    4. et al
    . Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J 2006; 27: 1229–1235.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Barbe F,
    2. Duran-Cantolla J,
    3. Capote F,
    4. et al
    . Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181: 718–726.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Pepin JL,
    2. Tamisier R,
    3. Barone-Rochette G,
    4. et al
    . Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 182: 954–960.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Barbe F,
    2. Duran-Cantolla J,
    3. Carmona C,
    4. et al
    . Effect of CPAP treatment on the incidence of cardiovascular events and hypertension in non-sleepy OSAS patients. A long-term RCT. Am J Respir Crit Care Med 2010; 181: A5559
    OpenUrl
  22. ↵
    1. Parati G,
    2. Lombardi C,
    3. Hedner J,
    4. et al
    . Recommendations for the management of patients with obstructive sleep apnoea and hypertension. Eur Respir J 2013; 41: 523–538.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Parati G,
    2. Lombardi C,
    3. Hedner J,
    4. et al
    . Position paper on the management of patients with obstructive sleep apnea and hypertension: Joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (Cooperation in Scientific and Technological Research) Action B26 on obstructive sleep apnea. J Hypertens 2012; 30: 633–646.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Fietze I,
    2. Penzel T,
    3. Alonderis A,
    4. et al
    . Management of obstructive sleep apnea in Europe. Sleep Med 2011; 12: 190–197.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Alonderis A,
    2. Barbe F,
    3. Bonsignore M,
    4. et al
    . Medico-legal implications of sleep apnoea syndrome: driving license regulations in Europe. Sleep Med 2008; 9: 362–375.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Rodenstein D
    Cost-B26 Action on Sleep Apnoea Syndrome. Driving in Europe: the need of a common policy for drivers with obstructive sleep apnoea syndrome. J Sleep Res 2008; 17: 281–284.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 41 Issue 3 Table of Contents
European Respiratory Journal: 41 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sleep apnoea and hypertension: time for recommendations
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Sleep apnoea and hypertension: time for recommendations
Patrick Lévy, Walter T. McNicholas
European Respiratory Journal Mar 2013, 41 (3) 505-506; DOI: 10.1183/09031936.00007213

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Sleep apnoea and hypertension: time for recommendations
Patrick Lévy, Walter T. McNicholas
European Respiratory Journal Mar 2013, 41 (3) 505-506; DOI: 10.1183/09031936.00007213
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • Sleep medicine
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • SARS-CoV-2-induced senescence as a potential therapeutic target
  • Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe Covid-19?
  • Update March 2022: management of hospitalised adults with coronavirus disease-19 (COVID-19): a European Respiratory Society living guideline
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society